Sibutramine High Quality Diet Medicine Raw Material Burning Fat CAS Number: 106650-56-0 Weight Loss Sibutramine
1. Product title:Sibutramine
2. Product parameter table:
|Appearance||White powder||Main Effect||To lose weight|
|Brand Name||Kan Ying||Store-method||Cool Dry Place|
|Shelf Life||2 Years When
Sibutramine (Meridia in the United States and Reductil in Europe and other countries) has been available in the United States since March 1998. It is a selective reuptake inhibitor of serotonin and norepinephrine into neurons, but does not act on any known receptors. Sibutramine promotes satiety, but can also increase energy expenditure by blocking the decrease in metabolic rate that accompanies weight loss. In a randomized, placebo-controlled, 6-month dose-range study of 1,047 patients, doses of 1 to 30 mg/ day had a significant dose-response effect. In the study, 67 percent of subjects treated with sibutramine lost 5 percent of their body weight from baseline, and 35 percent lost 10 percent or more. 136 In a one-year trial of 456 patients receiving sibutramine (10 or 15 mg/day) or placebo, 56% of patients who stayed in the trial for 12 months lost at least 5% of their initial body weight, and 30% of patients lost 10% of their initial body weight on a 10 mg dose. 137 In a trial in which initial weight loss was achieved by eating a very low-calorie diet before being randomly assigned to sibutramine (10 mg/day) or placebo, sibutramine produced additional weight loss, while placebo treated patients regained weight. 134138
Sibutramine is also effective in maintaining weight. Sibutramine reduction and maintenance of obesity trial (STORM) the sibutramine reduction and maintenance of obesity trial (STORM) began with a six-month open-label phase using sibutramine 10mg/day to induce weight loss. Patients who lost more than 8 kilograms were then randomly assigned to sibutramine or a placebo. 139 During the 18-month double-blind phase of the trial, placebo-treated patients steadily regained weight, maintaining only 20% of their weight loss at the end of the trial. In contrast, those treated with sibutramine maintained 80 percent of their weight loss after two years. Blood pressure levels in patients treated with sibutramine were still higher than those treated with placebo (see below). Clinical trials using sibutramine have shown that about 75% of patients treated with 15mg/day sibutramine lost more than 5% of their body weight, and 80% of these patients maintained this loss for two years if continued with the drug. In a meta-analysis of sibutramine clinical trials, 135 the drug produced a weighted mean weight loss of 6.35±6.47 kg (-13.9 lb) compared with 2.18±5.23 kg (-4.8 lb) in the placebo group, The net effect, or weight loss commonly referred to as placebo, was -4.16 kg (95%CI: −4.73 to -3.59).
Sibutramine is intolerant to about 5% of patients because of adverse effects on blood pressure and pulse. Some patients (about 25%) do not respond. This drug, like other sympathetic drugs, produces small increases in mean heart rate and mean blood pressure, as observed in clinical trials; However, the blood pressure response is variable. Sibutramine should be used with caution in patients with cardiovascular disease and in individuals taking selective serotonin reuptake inhibitors. It should not be used within two weeks of taking monoamine oxidase inhibitors or other norepinephrine drugs. A proportion (about 5%) of patients appear to be sensitive to the effects of blood pressure and cannot tolerate drugs. Other side effects, including dry mouth, insomnia and weakness, are similar to those of other norepinephrine drugs. Sibutramine was not associated with valvular heart disease, primary pulmonary hypertension, or substance abuse.